In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Hold rating on Morphic Holding (MORF – Research Report), with a price target of $30.00. The company’s shares closed yesterday at $27.98.
Thompson CFA covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, Dianthus Therapeutics, and Apogee Therapeutics, Inc.. According to TipRanks, Thompson CFA has an average return of 7.9% and a 42.31% success rate on recommended stocks.
Morphic Holding has an analyst consensus of Strong Buy, with a price target consensus of $57.43.
Based on Morphic Holding’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $45.29 million. In comparison, last year the company earned a revenue of $521 thousand and had a GAAP net loss of $36.14 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Morphic Holding (MORF) Company Description:
Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.
Read More on MORF:
